HISTORY
Based in Montreal, Neurenati Therapeutics is a pioneering biotechnology company focusing on the development of therapies for rare diseases. It was founded in 2020 by two academic researchers, Dr. Nicolas Pilon, a rare diseases and neural crest cell development expert, and Dr. Rodolphe Soret, a neuro-gastroenterology specialist. Dr. Pilon and Dr. Soret combined their expertise to develop an innovative treatment for Hirschsprung disease. With Dr. Maxime Ranger, a serial entrepreneur with extensive experience in drug development and biotechnology company startup, and supported by several experts in preclinical and clinical development, the Neurenati team is currently focusing its efforts on advancing its therapy for Hirschsprung disease.
OUR MISSION
Neurenati Therapeutics aims to advance the first non-surgical therapy for Hirschsprung disease into clinical trials. This treatment has for objective to regenerate a functional enteric nervous system, to restore intestinal epithelial barrier permeability, to reduce inflammation, and to reestablish a healthy microbiota in young patients with Hirschsprung disease. The goal of this approach is to provide an alternative to surgery, the only available treatment for Hirschsprung disease available to date, and increase the well-being and quality of life of affected patients.
Meet our team